Join Sensei Biotherapeutics for an investor webcast featuring Dr. Shiraj Sen, MD, PhD, Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas, who will join company management to discuss clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Dr. Sen is an investigator on the ongoing Phase 1/2 trial and lead author of the SNS-101 poster being presented on June 1, 2024 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

A live question and answer session will follow the formal presentation.